Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Allergan to Buy Vitae Pharmaceuticals for $639 Million
Allergan to Buy Vitae Pharmaceuticals for $639 Million
Allergan PLC agreed to acquire clinical-stage biotechnology company Vitae Pharmaceuticals Inc.
Japan's Takeda prepares $15 billion for U.S. acquisitions - FT
Japan's Takeda prepares $15 billion for U.S. acquisitions - FT
TOKYO -  Wed Sep 14, 2016 -- Takeda Pharmaceutical Co Ltd, Japan's leading drug maker, is ready to spend as much as $15 billion (11.
Bayer's Monsanto acquisition to face politically charged scrutiny
Bayer's Monsanto acquisition to face politically charged scrutiny
As the global agricultural sector races to consolidate, Bayer AG's $66 billion all-cash deal to acquire Monsanto Co will test growing political and consumer unease in the United States and abroad ...
Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes
Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes
SAN DIEGO, CA, USA I September 13, 2016 I Ligand Pharmaceuticals Incorporated (Nasdaq.
ChemDiv is presenting at the SCI's event: Innovation in Design, Supply and Acquisition for Compound Screening Libraries, on 14th September 2016 in Hatfield, UK
ChemDiv is presenting at the SCI's event: Innovation in Design, Supply and Acquisition for Compound Screening Libraries, on 14th September 2016 in Hatfield, UK
‪Dr.
Combination therapy with Glutaminyl Cyclase (QC) inhibitor PQ912 and pGlu-Abeta specific antibody PBD-C06 shows clear additive effects in reducing pGlu-Abeta as well as Abeta in Alzheimer-mouse model
Combination therapy with Glutaminyl Cyclase (QC) inhibitor PQ912 and pGlu-Abeta specific antibody PBD-C06 shows clear additive effects in reducing pGlu-Abeta as well as Abeta in Alzheimer-mouse model
HALLE (SAALE), Germany I September 13, 2016 I Probiodrug AG (Euronext Amsterdam.
Horizon Pharma Is Buying Raptor to Build Up Its Rare Disease Treatments
Horizon Pharma Is Buying Raptor to Build Up Its Rare Disease Treatments
Horizon Pharma HZNP 0.
Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
REHOVOT, Israel and BRIDGEWATER, N.
Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek® 2016
Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek® 2016
REDWOOD CITY, CA, USA I September 9, 2016 I Heron Therapeutics, Inc.
GTx Achieves Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer
GTx Achieves Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer
MEMPHIS, TN, USA I September 8, 2016 I GTx, Inc.
Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer’s Disease
Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer’s Disease
CAMBRIDGE, MA, USA I September 7 2016 I Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that it has initiated a Phas...
Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation
Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation
OSAKA, Japan and FLORHAM PARK, NJ, USA I September 7, 2016 I Shionogi today presented positive results of a 52-week, placebo-controlled, phase III study (COMPOSE III) of naldemedine in treatin...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand